Ferriprox FDA Approval History

Last updated by Judith Stewart, BPharm on May 3, 2021.

FDA Approved: Yes (First approved October 14, 2011)
Brand name: Ferriprox
Generic name: deferiprone
Dosage form: Tablets and Oral Solution
Company: ApoPharma Inc.
Treatment for: Thalassemia, Iron Overload, Sickle Cell Anemia

Ferriprox (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload in:

• thalassemia syndromes
• sickle cell disease or other anemias.

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age and Ferriprox Oral Solution is indicated in patients ≥3 years of age.

Development timeline for Ferriprox

Date	Article
May  1, 2021	Approval Chiesi Global Rare Diseases Announces FDA Approval of Ferriprox (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease
May 21, 2020	Approval Chiesi Group Receives FDA Approval for Ferriprox (deferiprone) Twice-a-Day Tablets
Oct 14, 2011	Approval FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Sep 14, 2011	ApoPharma Announces FDA Advisory Committee Recommendation in Favor of Ferriprox (deferiprone) Approval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer